Reporting dated May 30 states that researchers reported blocking the GPNMB protein responsible for spreading toxic immune cells in neural tissues.
Targeting GPNMB reduced immune-mediated neural damage in study models.
Scientists said the approach requires further human trials before therapeutic application.
Researchers blocked the GPNMB protein implicated in spreading toxic immune cells in Parkinson’s brain tissue. The account draws on verified materials available as of May 30, 2026.
According to available records, the clinical trial mapped inflammatory pathways that accelerate neurodegenerative progression.
Named entities in source reporting include GPNMB, Parkinson’s researchers.
The reporting cites named institutions and locations tied to the underlying event.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/news/health_medicine/parkinsons-protein-block-31